Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Cairns, Matthew ^a   Gosling, Roly ^a   Carneiro, Ilona ^a   Gesase, Samwel ^b   Mosha, Jacklin F ^c   Hashim, Ramadhan ^b   Kaur, Harparkash ^a   Lemnge, Martha ^b   Mosha, Frank W ^c   Greenwood, Brian ^a   Chandramohan, Daniel ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^c KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROGUANIL PLUS DAPSONE; FANSIDAR; FOLIC ACID ANTAGONIST; MEFLOQUINE; PLACEBO; ANTIMALARIAL AGENT; CHLOROGUANIL, DAPSONE DRUG COMBINATION; DAPSONE; DRUG DERIVATIVE; PROGUANIL; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ARTICLE; CALCULATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALARIA; POISSON DISTRIBUTION; POPULATION; PROTECTION; RANDOMIZED CONTROLLED TRIAL; TANZANIA; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG RESISTANCE; IMMUNIZATION; METHODOLOGY; NEWBORN; PEDIATRICS; TIME; TREATMENT OUTCOME;

ANTIMALARIALS; DAPSONE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; MALARIA; MEFLOQUINE; PEDIATRICS; PLACEBOS; PROGUANIL; PYRIMETHAMINE; RESEARCH DESIGN; SULFADOXINE; TANZANIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 77949662689     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009467     Document Type: Article

References (34)

1. Committee on the Perspectives on the Role of Intermittent Preventive Treatment for Malaria in Infants (2008) Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report. National Academies Press.
2. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, et al. (2009) Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374: 1533-1542.
3. Greenwood B (2006) Review: Intermittent preventive treatment - a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Tropical Medicine & International Health 11: 983-991.
4. ter Kuile FO, van Eijk AM, Filler SJ (2007) Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. Jama 297: 2603-2616.
5. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, et al. (2001) Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357: 1471-1477.
6. Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, et al. (2005) Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365: 1481-1483.
7. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, et al. (2005) Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. British Medical Journal 331: 727-733.
8. Macete E, Aide P, Aponte JJ, Sanz S, Mandomando I, et al. (2006) Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: A randomized, placebo-controlled trial. Journal of Infectious Diseases 194: 276-285.
9. Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, et al. (2007) A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin Infect Dis 45: 16-25.
10. Mockenhaupt FP, Reither K, Zanger P, Roepcke F, Danquah I, et al. (2007) Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrob Agents Chemother 51: 3273-3281.
11. Grobusch MP, Lell B, Schwarz NG, Gabor J, Dornemann J, et al. (2007) Intermittent Preventive Treatment against Malaria in Infants in Gabon-A Randomized, Double-Blind, Placebo-Controlled Trial. J Infect Dis 196: 1595-1602.
12. White NJ (2005) Intermittent presumptive treatment for malaria. PLoS Med 2: e3.
13. Cairns M, Carneiro I, Milligan P, Owusu-Agyei S, Awine T, et al. (2008) Duration of Protection against Malaria and Anaemia Provided by Intermittent Preventive Treatment in Infants in Navrongo, Ghana. PLoS ONE 3: e2227.
14. May J, Adjei S, Busch W, Gabor JJ, Issifou S, et al. (2008) Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon. Malar J 7: 198.
15. Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, et al. (2009) Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 374: 1521-1532.
16. Simpson JA, Hughes D, Manyando C, Bojang K, Aarons L, et al. (2006) Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. Br J Clin Pharmacol 61: 289-300.
17. Karbwang J, White NJ (1990) Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 19: 264-279.
18. Smith T, Felger I, Tanner M, Beck HP (1999) Premunition in Plasmodium falciparum infection: insights from the epidemiology of multiple infections. Trans R Soc Trop Med Hyg 93 Suppl 1: 59-64.
19. Achtman AH, Bull PC, Stephens R, Langhorne J (2005) Longevity of the immune response and memory to blood-stage malaria infection. Curr Top Microbiol Immunol 297: 71-102.
20. White NJ (1997) Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41: 1413-1422.
21. Bødker R, Akida J, Shayo D, Kisinza W, Msangeni HA, et al. (2003) Relationship between altitude and intensity of malaria transmission in the Usambara Mountains, Tanzania. J Med Entomol 40: 706-717.
22. Schellenberg D, Menendez C, Aponte J, Guinovart C, Mshinda H, et al. (2004) The changing epidemiology of malaria in Ifakara Town, southern Tanzania. Trop Med Int Health 9: 68-76.
23. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, et al. (2008) The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 5: e38.
24. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, et al. (2009) High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS ONE 4: e4569.
25. Clayton D, Hills M (1993) Statistical Models in Epidemiology. Oxford: Oxford University Press.
26. Aubouy A, Fievet N, Bertin G, Sagbo JC, Kossou H, et al. (2007) Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health 12: 886-894.
27. Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, et al. (2001) Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 358: 1218-1223.
28. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, et al. (2002) Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185: 380-388.
29. Watkins WM, Mberu EK, Winstanley PA, Plowe CV (1997) The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 13: 459-464.
30. White NJ (2008) How antimalarial drug resistance affects post treatment prophylaxis. Malar J 7: 9.
31. White NJ (2002) The assessment of antimalarial drug efficacy. Trends Parasitol 18: 458-464.
32. Dzinjalamala FK, Macheso A, Kublin JG, Taylor TE, Barnes KI, et al. (2005) Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. Antimicrobial Agents and Chemotherapy 49: 3601-3606.
33. Stepniewska K, White NJ (2008) Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 52: 1589-1596.
34. White N (1999) Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 354: 739-749.